Van Sandwick's Contact Details

Van Sandwick's Company Details

biomea fusion

Redwood City, California, United States • 11 - 50 Employees
Biotechnology

We are a biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs including greater target selectivity, lower drug exposure and the ability to drive a deeper, more durable response.Leveraging our extensive expertise in covalent binding chemistry and development, we built our proprietary FUSION™ System platform to advance a pipeline of novel covalent therapies. Our lead product candidate, BMF-219, is an orally bioavailable, potent and selective covalent inhibitor of MENIN, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Beyond BMF-219, we are utilizing our novel platform to develop covalent treatments against other high-value oncogenic drivers of cancer. Our goal is to utilize our capabilities and platform to become a leader in developing covalent small molecules in order to maximize the depth and durability of clinical benefit when treating various cancers.The name biomea derives from the Greek word bios, meaning "life," and the Latin word mea, meaning "my."At Biomea Fusion, we develop medicines to improve the life of the individual.